Evidence map›Paper›PMID 30940675›Full record

ArticleEMBO molecular medicine2019

DNA methylation inhibitor attenuates polyglutamine-induced neurodegeneration by regulating Hes5.

Naohide Kondo, Genki Tohnai, Kentaro Sahashi, Madoka Iida, Mayumi Kataoka, Hideaki Nakatsuji, Yutaka Tsutsumi, Atsushi Hashizume, Hiroaki Adachi, Haruki Koike and 4 more

Open access · goldAbstract read
In one paragraph

Article in EMBO molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Epigenetic control of skeletal muscle atrophy.Cellular & molecular biology letters · 2024
    Review
  4. Article
  5. Article
  6. Epigenetic regulation in Huntington's disease.Neurochemistry international · 2021
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Naohide KondoDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Genki TohnaiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kentaro SahashiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Madoka IidaDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Mayumi KataokaDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hideaki NakatsujiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yutaka TsutsumiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Atsushi HashizumeDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroaki AdachiDepartment of Neurology, University of Occupational and Environmental Health School of Medicine, Kitakyushu, Japan.ORCID 0000-0002-9302-4663
Haruki KoikeDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Keiko ShinjoDivision of Cancer Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yutaka KondoDivision of Cancer Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0003-3746-3191
Gen SobueResearch Division of Dementia and Neurodegenerative Disease, Nagoya University Graduate School of Medicine, Nagoya, Japan sobueg@med.nagoya-u.ac.jp ka2no@med.nagoya-u.ac.jp.ORCID 0000-0003-4769-5922
Masahisa KatsunoDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan sobueg@med.nagoya-u.ac.jp ka2no@med.nagoya-u.ac.jp.ORCID 0000-0001-9453-9311
Nagoya University · JPUniversity of Occupational and Environmental Health Japan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spinal and bulbar muscular atrophy (SBMA) is a polyglutamine-mediated neuromuscular disease caused by a CAG repeat expansion in the

Indexed as

DNA MethylationAgedAnimalsBasic Helix-Loop-Helix ProteinsCell SurvivalDNA (Cytosine-5-)-Methyltransferase 1HumansMice, Inbred C57BLMiddle AgedModels, BiologicalMotor ActivityMotor NeuronsMuscular Atrophy, SpinalNerve DegenerationPeptidesPhthalimidesBasic Helix-Loop-Helix ProteinsDNA (Cytosine-5-)-Methyltransferase 1Hes5 protein, mousePeptidesPhthalimidespolyglutamineReceptors, AndrogenRepressor ProteinsRG108Smad2 ProteinTryptophanDNA methylationepigeneticsHes5RG108spinal and bulbar muscular atrophy

Identifiers

PMID30940675
PMCPMC6505579
OpenAlexW2928870522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.